Real-Time Clinical Trials (RTCT) are no longer a future concept; they are the first sign that today’s operating models will need to evolve faster than most organizations expect. RTCTs allow Food and Drug Administration (FDA) reviewers to access live clinical data streams during an active study, rather than waiting for periodic data packages.  

On April 28, 2026, the FDA announced the initiation of two proof-of-concept (POC) RTCTs. This new initiative enables FDA reviewers to have access to clinical trial data in the cloud in real time. These RTCTs are designed to reduce historical lag time that can delay regulatory decisions by enabling a real-time view into safety signals and endpoints as a trial progresses.  

While the FDA’s RTCT initiative increases speed in drug development, it also acts as a signal that clinical development is shifting from retrospective review to live evidence generation. Organizations that continue to operate on quarterly data reviews and static listings will be structurally incompatible with where the FDA is heading. 

How RTCTs are Changing the Industry 

RTCTs will not replace the established clinical development phase immediately, but they may start to change the operating model of drug development as we know it. This POC will compress the time between data generation in trial, safety review, and regulatory review. The launch of these POCs signals that sponsors who can build governed real-time data flows will be in the best position against market competitors. 

In addition to accelerating programs, the implementation of real-time trials will make operational weaknesses impossible to hide. CROs that can’t operate in real time will no longer be able to claim operational excellence. Additionally, technology vendors face pressure to deliver interoperable, cloud‑native platforms capable of supporting continuous data flow and auditability. 

Preparing for RTCT 

While full real-time trials won’t become the norm overnight, the capabilities required to support them must begin development now. As the FDA tests clinical trials as a living data system, organizations must look internally and consider their readiness to support this new approach.  

Implementing RTCT would require assessing clinical operations, clinical development, data, and quality & regulatory perspective to determine end-to-end preparedness. True organizational readiness will come from businesses positioned to support processes like near real-time data ingestion and site connectivity, interim decision frameworks and adaptive protocols, and continuous quality assurance models.  

For pharmaceutical companies, the competitive edge will shift from who has the best molecule to who can generate and govern real‑time evidence. This means quality and regulatory teams will become real‑time decision partners, not end‑of‑line reviewers. 

The Importance of AI and Data Quality 

As the FDA evaluates these POCs, the next wave of expectations may include standardized data pipelines, interoperable platforms, and more frequent regulatory touchpoints. As real-time data becomes the norm, AI will shift from an experimental add–on to essential infrastructure, but only for organizations with the maturity to support continuous, high-quality data streams. AI amplifies the data and system it’s given: in low-maturity environments, it amplifies chaos; in real-time environments, it amplifies insight.  

For most organizations, investing in AI before fixing data flow, governance cadence, and quality controls will create more noise than value. The question is no longer whether real‑time trials will scale, but whether sponsors are ready when they do. The first step for sponsors is a readiness assessment that maps current data flows, governance cadence, and cross‑functional decision‑making against real‑time expectations. 

Looking Ahead 

RTCT is the first step toward clinical trials that function as living, continuously learning data systems. FDA’s real-time clinical trials initiative is not just about faster studies; it’s a test of whether clinical development can become a continuous, data-driven system. For sponsors, this will require shifting the established operating models to support data as it emerges. 

Our team at Clarkston has experience mapping governance, data flows, and roadmaps. If your organization is beginning to assess what RTCTs mean for your operating model, we can partner with you to support this shift. Click here to learn more.